Kelly Chibale (@kellychibale.bsky.social)

Introducing the potential binding interface between a TRAIL-mimicking peptide and DR5 via alanine scan. Tripathi et al. used experimental + in silico methods to learn how this 16-residue peptide binds to the death receptor DR5. pubs.acs.org/doi/10.1021/... #CancerResearch #ACSMedChemLett

loading . . .

Introducing the Potential Binding Interface between the TRAIL-Mimicking Peptide and DR5 via Alanine Scan Here we harnessed the unexplored binding interface between the 16-residue peptide (P) agonist and death receptor 5 (DR5). P is a solitary peptide ligand that mimics TRAIL (the natural ligand to death receptor) and is reported to control cancer growth in vivo selectively. We delved into the strategic merging of experimental and in silico structure–activity studies via the alanine scanning mutagenesis of P, wherein the disulfide bond was kept intact for structural integrity. Antiproliferative activity studies with these synthetic mutants on HCT116 cells enabled the mapping of the interaction engagement of each residue. Further, in silico docking and MD simulations led us to interpret and model the 3D interface of the binding site. Notably, Trp1, Leu4, Arg7, Ile8, Gln12, and Arg15 were projected experimentally as “hot-spot” residues crucial for primary interactions with DR5, which is predominantly supported via in silico investigations. This study is pivotal for developing new-generation peptide agonists that induce death receptor-mediated apoptosis. https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00071